Each year, we ask the question: if you gave the same molecule to two different companies in early phase, who would be more successful—and why?
Now in its 15th year, the Global Pharmaceutical Innovation and Invention Index is the longest‑running benchmark of pharmaceutical innovation, giving us a unique ability to distinguish structural performance from short‑term trends.
This year's top-performing companies consistently link platform science to late‑stage execution.
Early scientific boldness has been rewarded, but only where paired with disciplined clinical and regulatory follow‑through.
Geography is shifting. China’s growing influence as a source of both innovation and depth in invention in the global landscape has not been overlooked.
Better medicine depends on better decisions. Our Indices help make them. Stay tuned for the 2026 results, launching on May the 19th.
